Overview

Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and InderalĀ® LA Capsules 160 mg

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's propranolol hydrochloride extended-release 160 mg capsules to Wyeth's InderalĀ® LA 160 mg capsules following a single, oral 160 mg (1 x 160 mg) dose administered under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Propranolol